ライブ
CellmRNA 3′ UTRs chaperone intrinsically disordered regions to control protein activityClinical OMICsBeyond the Genome: Five Emerging Leaders in Epigenetics DiagnosticsBioPharma DiveStealthy startup Treeline plans a reverse merger10x Genomics Blog10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybizEndpoints NewsHow K Health moved AI chatbots into hospitals10x Genomics News10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - BioSpaceEndpoints NewsLilly offers up to $1B for Alzheimer's drug; Bial cuts failed Parkinson's drugEndpoints NewsTrodelvy misses in lung cancer, but Gilead and Merck have an HIV successFierceBiotechADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2, setting stage for pivotal programFierceBiotechLilly moves deeper into Alzheimer’s research with AlzeCure licensing dealFierceBiotechCancer biotech Parabilis ups IPO plans to potentially record-setting $637MEndpoints NewsEndpoints Women in Biopharma: Nominate for 2026
Thermo Fisher 2026年4月25日

Thermo Fisher Raises Outlook As Clario Deal Deepens AI Trial Capabilities - simplywall.st

Thermo Fisher Raises Outlook As Clario Deal Deepens AI Trial Capabilities - simplywall.st

原文
本文は利用できません。元の情報源をご確認ください。